Jubilant Ingrevia Acquires 100% Stake in Remidex Pharma for Rs. 16.5 Cr.
Jubilant Ingrevia Ltd has entered into a Share Purchase Agreement with Remidex Pharma Private Limited for the acquisition of its 100% stake. Remidex, incorporated in India on 15th June 1981, is a leading player in the manufacture of multivitamin premixes for nutritional products and food products. It has a high-grade manufacturing facility in Bangalore with all key certifications. The acquisition will enable Jubilant Ingrevia to move forward in the value chain towards Premixes in Human Nutrition, building upon its line of business of Vitamins (Vitamin B3 & B4). The transaction is subject to customary closing conditions and the cash consideration is Rs. 16.5 cr. Remidex's turnover for the last three years is as follows: FY 24-25: Rs. 24.27 Cr., FY 23-24: Rs. 31.15 Cr., FY 22-23: Rs. 30.51 Cr.
Key Highlights
- Jubilant Ingrevia to acquire 100% stake in Remidex Pharma for Rs. 16.5 cr.
- Remidex is a leading player in the manufacture of multivitamin premixes for nutritional products and food products.
- The acquisition will strengthen Jubilant Ingrevia's position in the Human Nutrition space.
- Remidex has a high-grade manufacturing facility in Bangalore with key certifications.
- Remidex's turnover for the last three years is: FY 24-25: Rs. 24.27 Cr., FY 23-24: Rs. 31.15 Cr., FY 22-23: Rs. 30.51 Cr.